Previous research demonstrated that TP53 was the most frequently mutated gene in CSF samples obtained from NSCLC patients with CNS metastases (14), and a similar study of NSCLC–LM patients who experienced disease progression on osimertinib also found that TP53 was the most frequently detected concurrent gene in the CSF and that EGFR amplification and C797S mutation were also observed (18), shedding light on the potential resistance mechanisms among NSCLC–LM patients treated with EGFR-TKIs. This evidence concerns the gene TP53 and non-small cell lung carcinoma.